Literature DB >> 7888800

Coronary heart disease at altitude.

J K Alexander1.   

Abstract

In the past, it has been assumed that some basic physiologic responses to altitude, exposure in coronary patients are comparable to those in normal young subjects. In fact there are similar changes in sympathetic activation, heart rate, and blood pressure early after ascent, with decrements in plasma volume, cardiac output, and stroke volume as acclimatization proceeds. These responses are described, and experience with coronary patients is reviewed. During the 1st 2 to 3 days at altitude, coronary patients are at greatest risk of untoward events. Gradual rather than abrupt ascent, a moderate degree of physical conditioning, early limitation of activity to a level tolerated at low altitude for somewhat less), and attention to blood pressure control all appear to have protective effects. Ascent to moderate altitude appears to entail little risk in coronary patients who are asymptomatic or have moderate exercise tolerance, provided that the above precautions are observed and that activity does not exceed levels at lower altitude. If activity is to be increased, pre-ascent treadmill exercise testing or Holter monitor data secured under conditions comparable to those anticipated at altitude may provide reasonable guidelines. For coronary patients previously evaluated and known to be in a high-risk category, indications for ascent should be examined more critically, and precautionary measures should be more rigorous. Advice for patients with known coronary disease who may desire to trek at very high altitude must involve individual evaluation, and guidelines remain elusive.

Entities:  

Mesh:

Year:  1994        PMID: 7888800      PMCID: PMC325187     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  27 in total

1.  MORTALITY FROM HEART DISEASE AT HIGH ALTITUDE. THE EFFECT OF HIGH ALTITUDE ON MORTALITY FROM ARTERIOSCLEROTIC AND HYPERTENSIVE HEART DISEASE.

Authors:  W E MORTON; D J DAVIDS; J A LICHTY
Journal:  Arch Environ Health       Date:  1964-07

2.  Exercise in an hypoxic environment as a screening test for ischaemic heart disease.

Authors:  P K Khanna; S K Dham; R S Hoon
Journal:  Aviat Space Environ Med       Date:  1976-10

3.  Altitude and arteriosclerotic heart disease mortality in white residents of 99 of the 100 largest cities in the United States.

Authors:  A W Voors; W D Johnson
Journal:  J Chronic Dis       Date:  1979

Review 4.  Cardiovascular adaptation to exercise at high altitude.

Authors:  R F Grover; J V Weil; J T Reeves
Journal:  Exerc Sport Sci Rev       Date:  1986       Impact factor: 6.230

5.  Impairment of myocardial O2 supply due to hyperventilation.

Authors:  W A Neill; M Hattenhauer
Journal:  Circulation       Date:  1975-11       Impact factor: 29.690

6.  Mechanism of reduced cardiac stroke volume at high altitude.

Authors:  J K Alexander; R F Grover
Journal:  Clin Cardiol       Date:  1983-06       Impact factor: 2.882

7.  Dickinson W. Richards Lecture: Circulatory adjustments to hypoxia.

Authors:  D D Heistad; F M Abboud
Journal:  Circulation       Date:  1980-03       Impact factor: 29.690

8.  Hypoxemia increases plasma catecholamine concentrations in exercising humans.

Authors:  P Escourrou; D G Johnson; L B Rowell
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-11

9.  Short-term adaptation to moderate altitude. Patients with chronic obstructive pulmonary disease.

Authors:  W G Graham; C S Houston
Journal:  JAMA       Date:  1978-09-29       Impact factor: 56.272

10.  Reduction in mortality from coronary heart disease in men residing at high altitude.

Authors:  E A Mortimer; R R Monson; B MacMahon
Journal:  N Engl J Med       Date:  1977-03-17       Impact factor: 91.245

View more
  1 in total

1.  Risk assessment for a high-altitude alpinist with coronary artery disease.

Authors:  Enrico Vizzardi; Marialma Berlendis; Edoardo Sciatti; Ivano Bonadei; Filippo Quinzani; Gian Tassi; Marco Metra
Journal:  Heart Lung Vessel       Date:  2015
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.